Key Launches Ahead But Vifor Plots More Pipeline Deals
Solid 2020 In Spite Of COVID-19 Impact
Stefan Schulze, CEO of the Swiss iron deficiency and kidney disease specialist, tells Scrip that Vifor's reputation as a go-to industry partner should result in at least two more licensing deals or product acquisitions in 2021.
You may also be interested in...
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.